MDGL: Madrigal Pharmaceuticals, Inc. Stock

by  •  • Comments Off on MDGL: Madrigal Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4,481.92
Enterprise Value ($M) 4,497.48
Book Value ($M) 405.33
Book Value / Share 19.31
Price / Book 11.06
NCAV ($M) 402.07
NCAV / Share 19.15
Price / NCAV 11.15

Profitability (mra)
Return on Invested Capital (ROIC) -0.72
Return on Assets (ROA) -1.12
Return on Equity (ROE) -2.49

Liquidity (mrq)
Quick Ratio 5.38
Current Ratio 5.38

Balance Sheet (mrq) ($M)
Current Assets 637.28
Assets 640.55
Liabilities 235.21
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -380.50
Net Income -373.63
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -324.23
Cash from Investing -502.52
Cash from Financing 595.12

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-25 13D/A Baker Bros. Advisors Lp 9.99 4.17
02-14 13G/A Armistice Capital, Llc 0.25 -75.96
02-14 13G/A Avoro Capital Advisors LLC 9.90 37.88
02-14 13G/A Paulson & Co. Inc. 5.60 10.57
02-13 13G/A Janus Henderson Group Plc 14.70 -4.62
02-13 13G/A Vanguard Group Inc 7.98 24.35
01-29 13G/A BlackRock Inc. 6.10 22.91
01-22 13G/A State Street Corp 3.55 -44.43
12-13 13D/A Bay City Capital Llc 2.90 -72.14

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION R
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPOR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-23 75,216 355,466 21.16
2024-04-22 132,390 680,651 19.45
2024-04-19 140,930 207,929 67.78
2024-04-18 66,078 95,695 69.05

(click for more detail)

Similar Companies
LXRX – Lexicon Pharmaceuticals, Inc. LYEL – Lyell Immunopharma, Inc.
MCRB – Seres Therapeutics, Inc. ME – 23andMe Holding Co.
MGNX – MacroGenics, Inc.


Financial data and stock pages provided by
Fintel.io